Roche arthritis drug beats Humira in clinical study

Swiss drug giant Roche ($RHHBY) has happily unveiled data from a Phase IV study that show its treatment Actemra--marketed in Europe as RoActemra--beat adalimumab or Humira in a head-to-heat study involving patients with rheumatoid arthritis. After 24 weeks of treatment, patients on Actemra monotherapy showed steeper drops in disease activity than those who took Abbott Laboratories' ($ABT) blockbuster drug Humira alone, Reuters reported. These results could become important as companies such as Roche and Abbott jockey for their shares of an increasingly crowded market for RA drugs. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.